entertainment -WSS

entertainment

author：comprehensive 2025-09-29 23:12:43 - browse：8349

A product image of the Cue reader COVID-19 home use test — Businesswire via AP

The Food and Drug Administration warned consumers Monday to not use Cue Health’s at-home Covid-19 tests. This follows an FDA warning letter to the company last week that said Cue was not following the conditions stipulated in the emergency use authorizations for its tests.

The FDA letters said the tests could give false results. Specifically, the agency said that the company had changed how the electrochemical signals within the test device were generated, received, and interpreted — changes the FDA has not authorized. These changes decreased the stability of the tests and might lead to false results, the agency said.

The FDA warnings come near what might be the end of a spectacularly bumpy ride for the company. When Cue went public in 2021, it was valued at nearly $3 billion. It supplied tests for the NBA’s 2020 “bubble,” leading a Trump administration official to proclaim that if the test was “good enough for LeBron,” the administration would bring it to the American people — and it did, in a $481 million deal.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Drinking less cuts risk of oral cavity, esophageal cancer: Report

explore

WSS

Free speech concerns arise in wake of journal editor Eisen's firing

CRISPR gene editing developments we’re watching in 2024

Why health care costs have stayed mostly flat since 2010

White House calls on federal agencies to crack down on AI abuses

Readout Newsletter: The latest on Moderna, Apellis, and Merck

Prime Medicine, Myeloid Therapeutics clash over genome

knowledge

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

focus

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Why health records don't always know when patients are dead

Medical records are filled with copy

Can sheer will power keep patients alive in their dying hours?

In age of alternative facts, a scholarly course on calling out crap

MoonLake credibility takes another hit with mid

Cancer drug shortages should be causing more outrage

MoonLake credibility takes another hit with mid

Malaria cases in Florida and Texas: Here’s what you need to know

FDA approves potent Eli Lilly obesity drug, Zepbound

focus

Drinking less cuts risk of oral cavity, esophageal cancer: Report

FDA approves potent Eli Lilly obesity drug, Zepbound

MoonLake credibility takes another hit with mid

A clever new way to fix Medicaid and graduate medical education

SEC charges former device maker CEO with $41 million fraud

More doctors should go into startup world

knowledge

explore

explore

explore